Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC).

Trial Profile

Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Sep 2015 to 1 Apr 2017.
    • 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
    • 06 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Mar 2015, as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top